Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers

George D. Demetri, MD
Published: Tuesday, Jul 12, 2016


George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, explains how sarcoma treatment has influenced the treatment of other cancers.
 
Sarcoma continues to pave the way for what is happening in other cancers, says Demetri. The disease is broken down into over 500 different subtypes, each with their own treatment specifications. This method is now being applied in lung, breast, and colorectal cancers, says Demetri.
 
Some cancers have also been decommissioned, and are not longer consider carcinomas at all.
 

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, explains how sarcoma treatment has influenced the treatment of other cancers.
 
Sarcoma continues to pave the way for what is happening in other cancers, says Demetri. The disease is broken down into over 500 different subtypes, each with their own treatment specifications. This method is now being applied in lung, breast, and colorectal cancers, says Demetri.
 
Some cancers have also been decommissioned, and are not longer consider carcinomas at all.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x